BEAM
Price
$26.74
Change
+$3.37 (+14.42%)
Updated
Dec 3 closing price
Capitalization
2.71B
89 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$5.18
Change
+$0.08 (+1.57%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
405.91M
Intraday BUY SELL Signals
Interact to see
Advertisement

BEAM vs SLDB

Header iconBEAM vs SLDB Comparison
Open Charts BEAM vs SLDBBanner chart's image
Beam Therapeutics
Price$26.74
Change+$3.37 (+14.42%)
Volume$2.66M
Capitalization2.71B
Solid Biosciences
Price$5.18
Change+$0.08 (+1.57%)
Volume$11.1K
Capitalization405.91M
BEAM vs SLDB Comparison Chart in %
View a ticker or compare two or three
VS
BEAM vs. SLDB commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BEAM is a Hold and SLDB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (BEAM: $23.37 vs. SLDB: $5.11)
Brand notoriety: BEAM and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BEAM: 31% vs. SLDB: 35%
Market capitalization -- BEAM: $2.44B vs. SLDB: $405.91M
BEAM [@Biotechnology] is valued at $2.44B. SLDB’s [@Biotechnology] market capitalization is $405.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BEAM’s FA Score shows that 1 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • BEAM’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than BEAM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BEAM’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • BEAM’s TA Score: 4 bullish, 5 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SLDB is a better buy in the short-term than BEAM.

Price Growth

BEAM (@Biotechnology) experienced а -5.35% price change this week, while SLDB (@Biotechnology) price change was -0.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

BEAM is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BEAM($2.71B) has a higher market cap than SLDB($406M). SLDB YTD gains are higher at: 27.750 vs. BEAM (-5.766). SLDB has higher annual earnings (EBITDA): -152.11M vs. BEAM (-414.33M). BEAM has more cash in the bank: 1.15B vs. SLDB (268M). SLDB has less debt than BEAM: SLDB (23.1M) vs BEAM (155M). BEAM has higher revenues than SLDB: BEAM (60.3M) vs SLDB (0).
BEAMSLDBBEAM / SLDB
Capitalization2.71B406M668%
EBITDA-414.33M-152.11M272%
Gain YTD-5.76627.750-21%
P/E RatioN/AN/A-
Revenue60.3M0-
Total Cash1.15B268M429%
Total Debt155M23.1M671%
FUNDAMENTALS RATINGS
BEAM vs SLDB: Fundamental Ratings
BEAM
SLDB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4046
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (21) in the Biotechnology industry is in the same range as BEAM (30) in the null industry. This means that SLDB’s stock grew similarly to BEAM’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BEAM (100) in the null industry. This means that SLDB’s stock grew similarly to BEAM’s over the last 12 months.

BEAM's SMR Rating (96) in the null industry is in the same range as SLDB (98) in the Biotechnology industry. This means that BEAM’s stock grew similarly to SLDB’s over the last 12 months.

BEAM's Price Growth Rating (40) in the null industry is in the same range as SLDB (46) in the Biotechnology industry. This means that BEAM’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for BEAM (100) in the null industry. This means that SLDB’s stock grew significantly faster than BEAM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BEAMSLDB
RSI
ODDS (%)
N/A
Bullish Trend 6 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
87%
Momentum
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
82%
MACD
ODDS (%)
Bullish Trend 6 days ago
87%
Bullish Trend 6 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 6 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
82%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BEAM
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TRIRX80.11N/A
N/A
Nuveen Large Cap Gr Idx Retire
TINCX2.85N/A
N/A
Templeton Global Dynamic Income A1
UIAGX80.68N/A
N/A
Victory Aggressive Growth Institutional
UGEIX13.03N/A
N/A
Victory Global Equity Income
TOTFX11.70N/A
N/A
Transamerica Mid Cap Value Opps R4

BEAM and

Correlation & Price change

A.I.dvisor indicates that over the last year, BEAM has been closely correlated with CRSP. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if BEAM jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BEAM
1D Price
Change %
BEAM100%
-2.83%
CRSP - BEAM
70%
Closely correlated
-1.13%
RXRX - BEAM
61%
Loosely correlated
-0.69%
NTLA - BEAM
61%
Loosely correlated
-3.74%
PRME - BEAM
60%
Loosely correlated
-5.71%
AXON - BEAM
57%
Loosely correlated
+0.91%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-1.92%
EDIT - SLDB
48%
Loosely correlated
-3.65%
BEAM - SLDB
47%
Loosely correlated
-2.83%
DSGN - SLDB
47%
Loosely correlated
+0.11%
SYRE - SLDB
47%
Loosely correlated
-0.91%
RGNX - SLDB
45%
Loosely correlated
-3.10%
More